STAAR Surgical's recovery appears fragile, with Q2 2026 revenue flatlining at $93.5M after a volatile period, suggesting the 111% YoY growth is largely a function of depressed prior-year comparisons.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $0.11+116.7% vs $0.05 | $83M+5.9% vs $79M |
Q3 2026 Aug 12, 2026 | $0.16-27.7% vs $0.22 | $94M+3.2% vs $91M |
Q2 2026 May 13, 2026 | $0.38+600.8% vs $0.05 | $94M+18.8% vs $79M |
Q2 2026 Mar 3, 2026 | -$0.20-211.1% vs $0.18 | $58M-22.9% vs $75M |
STAAR Surgical (NASDAQ: STAA) reported lower third-quarter sales and profit on a reported basis, but said revenue rose 21% after excluding a prior-year deferred sales item in China. The implantable lens maker also said demand for higher-priced products in China exceeded its ability to supply them during the quarter. Net sales for the third quarter of
STAAR Surgical Company (STAA) Q3 2026 Earnings Call Transcript
Staar Surgical (STAA) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.46 per share a year ago.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended October 2, 2026. The Company will host an earnings call and webcast today at 5:30 PM Eastern Time. Third Quarter and Year-to-Date 2026 Highlights Include: Net sales down 12% Y/Y; up 21% excluding a 33-percentage point ($25.9.
Benchmark STAA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for STAAR Surgical Company (STAA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.21 | $1.26B | 2447.57 | -23.72% | 0.16% | 0.15% | — | |
| $166.00 | $11.89B | 23.97 | 0.9% | 11.83% | 11.76% | — | |
| $100.61 | $6.55B | 25.50 | 0.5% | 17.28% | 21.72% | — | |
| $88.24 | $3.05B | 24.94 | 37.13% | 19.85% | 28.38% | — | |
| $102.14 | $58.81B | 57.77 | 11.55% | 15.3% | 9.65% | — | |
| $58.54 | $2.98B | 195.98 | 14.88% | 2.52% | 2.93% | — |
STAAR Surgical Company (STAA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
STAAR Surgical Company (STAA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 12, 2026·SEC
Aug 6, 2026·SEC
Jun 22, 2026·SEC
Get notified when STAA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
STAAR Surgical Company (STAA) stock FAQ — growth, dividends, profitability & financials explained
STAAR Surgical Company (STAA) reported $328.3M in revenue over the trailing twelve months. Revenue was $239.4M in fiscal year 2025. That is 467% more than the $42.2M of fiscal year 1996.
STAAR Surgical Company (STAA) grew revenue by 42.4% over the trailing twelve months, compared with the twelve months before.
Yes. STAAR Surgical Company (STAA) earned $0.5M in net income over the trailing twelve months (a 0.2% net margin).
STAAR Surgical Company (STAA) had a return on equity (ROE) of 0.1% over the trailing twelve months. That is below the market's typical 10-15%.
STAAR Surgical Company (STAA) generated $17.8M in free cash flow over the trailing twelve months.
